Receptor-tyrosine-kinase-targeted Therapies for Head and Neck Cancer

Overview

Journal J Signal Transduct

Date 2011 Jul 22

PMID 21776391

Citations 13

Authors

Lisa A Elferink

Vicente A Resto

Affiliations

Soon will be listed here.

Abstract

Molecular therapeutics for treating epidermal growth factor receptor-(EGFR-) expressing cancers are a specific method for treating cancers compared to general cell loss with standard cytotoxic therapeutics. However, the finding that resistance to such therapy is common in clinical trials now dampens the initial enthusiasm over this targeted treatment. Yet an improved molecular understanding of other receptor tyrosine kinases known to be active in cancer has revealed a rich network of cross-talk between receptor pathways with a key finding of common downstream signaling pathways. Such cross talk may represent a key mechanism for resistance to EGFR-directed therapy. Here we review the interplay between EGFR and Met and the type 1 insulin-like growth factor receptor (IGF-1R) tyrosine kinases, as well as their contribution to anti-EGFR therapeutic resistance in the context of squamous cell cancer of the head and neck, a tumor known to be primarily driven by EGFR-related oncogenic signals.

Citing Articles

New insights into RAS in head and neck cancer.

Jagadeeshan S, Novoplansky O, Cohen O, Kurth I, Hess J, Rosenberg A Biochim Biophys Acta Rev Cancer. 2023; 1878(6):188963.

PMID: 37619805 PMC: 11815531. DOI: 10.1016/j.bbcan.2023.188963.

Design, Synthesis, Anticancer Activity and Molecular Docking of New 1,2,3-Triazole-Based Glycosides Bearing 1,3,4-Thiadiazolyl, Indolyl and Arylacetamide Scaffolds.

Elganzory H, M Alminderej F, El-Bayaa M, Awad H, Nossier E, El-Sayed W Molecules. 2022; 27(20).

PMID: 36296551 PMC: 9611297. DOI: 10.3390/molecules27206960.

Mutations in Head and Neck Squamous Cell Carcinoma.

Nair S, Bonner J, Bredel M Int J Mol Sci. 2022; 23(7).

PMID: 35409179 PMC: 8999014. DOI: 10.3390/ijms23073818.

Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer: A Systematic Review.

Perrotti V, Caponio V, Mascitti M, Lo Muzio L, Piattelli A, Rubini C Cancers (Basel). 2021; 13(13).

PMID: 34206707 PMC: 8269333. DOI: 10.3390/cancers13133126.

Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers.

Ortiz-Cuaran S, Bouaoud J, Karabajakian A, Fayette J, Saintigny P Front Oncol. 2021; 11:614332.

PMID: 33718169 PMC: 7947611. DOI: 10.3389/fonc.2021.614332.

References

Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H . MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 2008; 68(11):4360-8. DOI: 10.1158/0008-5472.CAN-07-5960. View

Gill G, Kawamoto T, Cochet C, Le A, Sato J, Masui H . Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase.... J Biol Chem. 1984; 259(12):7755-60. View

Fung C, Grandis J . Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs. 2010; 15(3):355-73. PMC: 3133968. DOI: 10.1517/14728214.2010.497754. View

Trusolino L, Comoglio P . Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer. 2002; 2(4):289-300. DOI: 10.1038/nrc779. View

Tuynman J, Lagarde S, Ten Kate F, Richel D, van Lanschot J . Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br J Cancer. 2008; 98(6):1102-8. PMC: 2275481. DOI: 10.1038/sj.bjc.6604251. View

Cortesina G, Martone T, GALEAZZI E, Olivero M, De Stefani A, Bussi M . Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases. Int J Cancer. 2000; 89(3):286-92. View

Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S . The protein kinase complement of the human genome. Science. 2002; 298(5600):1912-34. DOI: 10.1126/science.1075762. View

Gupta A, McKenna W, Weber C, Feldman M, Goldsmith J, Mick R . Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res. 2002; 8(3):885-92. View

SESSIONS D, Spector G, Lenox J, Parriott S, Haughey B, Chao C . Analysis of treatment results for floor-of-mouth cancer. Laryngoscope. 2000; 110(10 Pt 1):1764-72. DOI: 10.1097/00005537-200010000-00038. View

10.

Kawamoto T, Sato J, Le A, Polikoff J, Sato G, Mendelsohn J . Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A. 1983; 80(5):1337-41. PMC: 393592. DOI: 10.1073/pnas.80.5.1337. View

11.

Chung C, Parker J, Karaca G, Wu J, Funkhouser W, Moore D . Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell. 2004; 5(5):489-500. DOI: 10.1016/s1535-6108(04)00112-6. View

12.

Grandis J, Tweardy D . Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993; 53(15):3579-84. View

13.

Cowin A, Kallincos N, Hatzirodos N, Robertson J, Pickering K, Couper J . Hepatocyte growth factor and macrophage-stimulating protein are upregulated during excisional wound repair in rats. Cell Tissue Res. 2001; 306(2):239-50. DOI: 10.1007/s004410100443. View

14.

Pugh C, Ratcliffe P . Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003; 9(6):677-84. DOI: 10.1038/nm0603-677. View

15.

Dequanter D, Shahla M, Paulus P, Lothaire P . Cetuximab in the treatment of head and neck cancer: preliminary results outside clinical trials. Cancer Manag Res. 2010; 2:165-8. PMC: 3004587. DOI: 10.2147/cmar.s11085. View

16.

Riely G, Pao W, Pham D, Li A, Rizvi N, Venkatraman E . Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006; 12(3 Pt 1):839-44. DOI: 10.1158/1078-0432.CCR-05-1846. View

17.

Barnes C, Ohshiro K, Rayala S, El-Naggar A, Kumar R . Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res. 2007; 13(14):4291-9. DOI: 10.1158/1078-0432.CCR-06-2040. View

18.

Kochupurakkal B, Harari D, Di-Segni A, Maik-Rachline G, Lyass L, Gur G . Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. J Biol Chem. 2004; 280(9):8503-12. DOI: 10.1074/jbc.M413919200. View

19.

Chakravarti A, Loeffler J, Dyson N . Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 2002; 62(1):200-7. View

20.

Masui H, Kawamoto T, Sato J, Wolf B, Sato G, Mendelsohn J . Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1984; 44(3):1002-7. View